Portal de Periódicos da CAPES

Mise à jour des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France

2010; Elsevier BV; Volume: 30; Issue: 5 Linguagem: Francês

10.1016/j.annpat.2010.07.001

2213-008X

Frédérique Penault–Llorca, Anne Vincent‐Salomon, Jean‐Pierre Bellocq, Marie-Christine Matthieu, Gaetan-Mac Grogan, Isabelle Treilleux, F. Ettore, Sophie Laberge, Brigitte Sigal, Jérôme Couturier, Magali Lacroix‐Triki, Martine Antoine, André Balaton, Marie‐Christine Baranzelli, Valérie Becette, Cécile Blanc‐Fournier, Frédéric Bibeau, Eva Brabencová, Sabrina Croce, Viviana Fridman, Pascal Génin, Jean‐Pierre Ghnassia, Jocelyne Jacquemier, B. Poulet, Pascal Roger, Christine Sagan, Patrick Tas, Martine Trassard, Véronique Verrièle, Laurent Arnould,

Cancer Treatment and Pharmacology

In Europe, patients who may benefit from an HER2 targeted drug are currently selected by immunohistochemistry (IHC). In situ hybridization (ISH) techniques should be used for complementary assessment of ambiguous 2+ IHC cases and for the calibration of the IHC technique. Eligibility to an HER2 target treatment is defined by an HER2 positive status being IHC test 3+ or 2+ amplified. Reliable detection of HER2 status is essential to the appropriate usage of HER2 targeted drugs because its specificity is limited to tumors overexpressing HER2. It is essential that the IHC evaluation of the HER2 status of a mammary carcinoma is optimized and reliable. This GEFPICS' guidelines look over the different steps of the IHC technique, the controls and, the rules for interpretation. Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs).